The recent introduction of a variety of molecular tests will potentially reshape the care of patients with prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
These tests may make more accurate management decisions possible for those patients who have been "overdiagnosed" with biologically indolent disease, which represents an exceptionally small mortality risk. There is a wide range of possible applications of these tests to different clinical scenarios in patient populations managed with active surveillance.
Cancer 2015. © 2015 American Cancer Society.
Cancer. 2015 Jul 6. doi: 10.1002/cncr.29496. [Epub ahead of print]
Reichard CA1, Stephenson AJ1, Klein EA1.
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.